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Background Head and neck cancer (HNC) risk is elevated among lean people
and reduced among overweight or obese people in some studies;
however, it is unknown whether these associations differ for certain
subgroups or are influenced by residual confounding from the
effects of alcohol and tobacco use or by other sources of biases.
Methods We pooled data from 17 case–control studies including 12 716 cases
and the 17 438 controls. Odds ratios (ORs) and 95% confidence
intervals (CIs) were estimated for associations between body mass
index (BMI) at different ages and HNC risk, adjusted for age, sex,
centre, race, education, tobacco smoking and alcohol consumption.
Results Adjusted ORs (95% CIs) were elevated for people with BMI
at reference (date of diagnosis for cases and date of selection for
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controls) 418.5 kg/m2 (2.13, 1.75–2.58) and reduced for BMI
425.0–30.0 kg/m2 (0.52, 0.44–0.60) and BMI 530 kg/m2 (0.43,
0.33–0.57), compared with BMI 418.5–25.0 kg/m2. These associa-
tions did not differ by age, sex, tumour site or control source.
Although the increased risk among people with BMI 418.5 kg/m2
was not modified by tobacco smoking or alcohol drinking, the
inverse association for people with BMI425 kg/m2 was present
only in smokers and drinkers.
Conclusions In our large pooled analysis, leanness was associated with increased
HNC risk regardless of smoking and drinking status, although reverse
causality cannot be excluded. The reduced risk among overweight or
obese people may indicate body size is a modifier of the risk asso-
ciated with smoking and drinking. Further clarification may be pro-
vided by analyses of prospective cohort and mechanistic studies.
Keywords BMI, head and neck cancer, smoking
Introduction
Cancers of the oral cavity, pharynx and larynx—
referred to collectively as head and neck cancer
(HNC)—account for a half a million cancer diagnoses
worldwide.1 Although in Europe and North America
75% of these cancers are attributed to tobacco
smoke and alcohol consumption,2–4 the large propor-
tion of patients who are non-smokers and non-
drinkers indicates that other factors may affect
risk of these cancers. Most previous studies5–13 have
found that people with a body mass index (BMI)
<18.5 kg/m2 experience a higher risk of HNC,
compared with people with a normal BMI (18.5
to <25.0 kg/m2). Among overweight (25.0 to
<30.0 kg/m2) or obese (430.0 kg/m2) people, HNC
risk appears to be lower than among those with a
normal BMI.5–13
The independent effect of body size on HNC is
difficult to assess because it is strongly affected
by alcohol drinking and cigarette smoking,14–16 the
two major risk factors for these malignancies. Even
following adjustment for alcohol and tobacco con-
sumption, the influence of residual confounding
cannot be easily discounted. The limited sample size
of previous reports based on individual studies has
hindered detailed examination of the association
with body size in the small proportion of non-smokers
and non-drinkers, among whom confounding by
cigarette smoking and alcohol consumption would
be especially minimized.
The International Head and Neck Cancer Epidemiol-
ogy (INHANCE) Consortium has pooled epidemiologic
studies of HNC to estimate the effects of risk factors
on HNC risk.3 The large number of cases assembled
by INHANCE allowed us to estimate more precisely
the association with BMI in non-smokers and non-
drinkers, as well as in smokers and drinkers. We also
examined other potentially important subgroups,
such as tumour site, sex and age, as well as the
possible methodological issue of whether controls
were selected from hospital populations or the gen-
eral population. In addition to weight at the time
of diagnosis, we also examined self-reported weight
2–5 years prior to diagnosis as an estimate of weight
prior to weight loss secondary to disease, and also
weight at age 20–30 years to evaluate the effects of
early body size.
Methods
Data pooling methods for the INHANCE consortium
have been previously described in detail elsewhere.3
The INHANCE consortium originally included 15 indi-
vidual case–control studies (version 1.1), including
10 244 cases and 15 227 controls.17–30 After our earlier
publication,3 four additional studies joined the
INHANCE consortium including two multicentre
studies based in the USA: the New York multicentre
study31 (covering New York City, Chicago, Hines, IL,
Detroit, MI, New Hyde Park, NY, East Meadow,
NW and Philadelphia) and the US multicentre
study (covering metropolitan Atlanta, Los Angeles,
Santa Clara and San Mateo counties south of San
Francisco-Oakland, and the state of New Jersey),32
and studies in Rome33 and Boston.34 In the current
analysis, we excluded the Iowa study (556 cases and
760 controls)30 that did not collect information about
weight and height, and the Rome study (278 cases
and 295 controls)33 because only weight was col-
lected. A total of 17 studies, including 9 in North
America, 7 in Europe and 1 in South America
(Table 1), contributed data to the current analyses
that included 12 716 cases and 17 438 controls,
which excluded 49 cases and 101 controls with miss-
ing data for age, sex or race/ethnicity and the site of
origin of their tumour.
Cases were defined as newly diagnosed cancers of
the oral cavity, pharynx, oral/pharynx not otherwise
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Table 1 Characteristics of the 12 716 cases and the 17 438
controls with data on body sizea
Characteristic Cases Controls
n % n %
Age (years)
12–39 500 3.9 1135 6.5
40–45 706 5.6 1240 7.1
45–49 1364 10.7 1920 11.0
50–54 1934 15.2 2701 15.5
55–59 2346 18.4 1994 11.4
60–64 2199 17.3 2724 15.6
65–69 1786 14.0 2305 13.2
70–74 1205 9.5 1627 9.3
75–94 676 5.3 791 4.5
Sex
Women 2759 21.7 5124 29.4
Men 9957 78.3 12314 70.6
Race
Non-Hispanic White 8870 69.8 13691 78.5
Black 682 5.4 770 4.4
Hispanic 208 1.6 428 2.5
Asian 629 4.9 665 3.8
Other 136 1.1 178 1.0
Brazilian 2191 17.2 1706 9.8
Study location
Italy multicentre 1261 9.9 2716 15.6
Latin America multicentre 2191 17.2 1706 9.8
IARC multicentre 1559 12.3 1676 9.6
Milan 416 3.8 1531 8.8
US multicentre 1114 8.8 1268 7.3
Los Angeles 417 3.3 1005 5.8
Central Europe 762 6.0 907 5.2
New York multicentre 1118 8.8 906 5.2
Tampa 207 1.6 897 5.1
Switzerland 516 4.1 883 5.1
Houston 829 6.5 865 5.0
Aviano 482 3.8 855 4.9
Boston 584 4.6 659 3.8
Seattle 407 3.2 607 3.5
Puerto Rico 350 2.8 521 3.0
France 323 2.5 234 1.3
North Carolina 180 1.4 202 1.2
Study design
Hospital-based studies 9844 77.4 13 378 76.7
Population-based studies 2872 22.6 4060 23.3
(continued)
Table 1 Continued
Characteristic Cases Controls
n % n %
Cigarette smoking status
Never 1341 10.5 6465 37.1
Ever 11 372 89.5 10 959 62.9
Missing 3 14
Pack-years of cigarette smoking
Never 1901 15.1 6827 39.6
1–10 858 6.8 2539 14.7
11–20 1146 9.1 1986 11.5
21–30 1620 12.9 1747 10.1
31–40 1838 14.6 1391 8.1
41–50 1546 12.3 977 5.7
450–441 3681 29.2 1790 10.4
Missing 126 181
Alcohol drinking status
Never 1786 14.1 4462 25.6
Ever 10915 85.9 12964 74.4
Missing 15 12
Number of alcohol drinks per day
Never 1786 14.7 4462 26.4
0 to <1 2192 18.1 4761 28.2
1 to <3 2338 19.3 3618 21.4
3 to <5 1522 12.5 1725 10.2
5 to 8512 4290 35.4 2305 13.7
Missing 588 567
Height (in metres)
0.65–1.64 3168 27.2 4434 26.9
1.65–1.69 2145 18.4 3138 19.0
1.70–1.74 2584 22.2 3508 21.3
1.75–2.13 3764 32.3 5414 32.8
Subsite of tumour
Oral cavity 3740 29.4
Oral cavity/pharynx NOS 3690 29.0
Oropharynx 917 7.2
Hypopharynx 1226 9.6
Larynx 2837 22.3
Head and neck overlap 306 2.4
Histology of tumour
Squamous cell 800 71.4
Other 320 28.6
Unknown 3596
aINHANCE pooled case–control study of HNC.
IARC¼ International Agency on Research for Cancer.
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specified (NOS) or larynx. For each study, controls
were frequency-matched on age and sex, and for
some studies: centre (Italy multicentre, Central
Europe, IARC multicentre and Latin America studies),
hospital (France study), ethnicity (Tampa and Los
Angeles studies) and neighbourhood (Los Angeles
study). The date of reference was defined as the
date of diagnosis for cases and the date of selection
for controls with the exception of the Seattle study. In
the Seattle study, the date of reference for controls
was selected at random from among the possible
case diagnosis dates.29 The wording of interview ques-
tions was compared across studies to determine data
similarities. Variables for ethnicity, education, tumour
site and histology, cigarette smoking, other tobacco
habits, alcohol consumption, height and weight
were pooled across studies, as described in detail else-
where3 and in brief below.
All height and weight variables were self-reported at
the time of interview. Adult height was missing for
1055 cases and 944 controls. Because each study quer-
ied weight for different time periods, the total number
of cases and controls differ by analysis. Weight at the
date of reference was self-reported for 11 547 cases
and 15 924 controls with the exception of Central
Europe and Seattle. Weight 2–5 years prior to refer-
ence was collected for 7654 cases and 9799 controls
(from studies: Central Europe, New York Multicentre,
Seattle, Boston, Latin America and IARC multicentre
studies), and weight between 20 and 30 years of age
for 7654 cases and 9799 controls (from studies:
Central Europe, Puerto Rico, Los Angeles, Latin
America, IARC multicentre, Italy multicentre and US
multicentre studies). BMI values were calculated as
weight (in kilograms) divided by height squared
(in square metres). We were not able to systematically
verify self-reported height and weight; therefore,
we included all BMI values. Few subjects had
values outside the physiological range (BMI < 11 or
460.0 kg/m2); specifically, three cases and five con-
trols for BMI at reference, four cases and four con-
trols for BMI 2–5 years prior to reference and six
cases and two controls for BMI at age 20–30 years
had BMI values 460.0 kg/m2. BMI values were
categorized according to the World Health Organiza-
tion definitions (418.5, 418.5–25.0, 425.0–30.0,
430.0 kg/m2).35 Height was categorized using quartiles
of the control distribution.
We used the definitions of smoking of cigarettes,
pipes and cigars, and alcohol drinking categories
adopted in a previous INHANCE publication.3
Although questions about tobacco use varied across
studies, never users of cigarettes, pipes and cigars did
not exceed either 1 year of cigarette smoking, 100 cig-
arettes in a lifetime or ever smoked ‘regularly’ (France
and Central Europe studies). Pack-years of cigarette
smoking was calculated by multiplying packs (defined
as 20 cigarettes) of cigarettes per day and number of
years smoking. In the alcohol section of the study
questionnaires, subjects were asked if they had been
alcohol drinkers, then asked subsequent questions on
frequency of drinking, duration of drinking and differ-
ent types of alcoholic beverages consumed (beer, wine,
hard liquors and aperitif). Definition of never drinkers
also varied by study, from 0 drinks in a lifetime (France,
Central Europe, Aviano, Milan, Italy multicentre and
Switzerland studies) to <4 drinks per month (North
Carolina study).3 To handle the different volume spec-
ification for each type of alcoholic beverage by study,
the number of drinks per day was calculated by the
frequency of consumption of each alcoholic beverage
type weighted by the corresponding duration with the
exception of France, Iowa and Tampa studies, in which
the average of the frequency of all alcoholic beverage
type was used in lieu of missing data for duration.3
For missing data on education level (703 cases and
487 controls for the analysis on BMI at diagnosis;
367 cases and 227 controls for the analysis on BMI
2–5 years prior to diagnosis; 318 cases and 229 con-
trols for the analysis on BMI at age 20–30 years),
we applied multiple imputation with the PROC
MI procedure in SAS Institute Inc software 9.0
(Cary, NC), for the studies within each of the four
geographic regions. We used a logistic regression
model36 to predict education level with age, sex,
race/ethnicity, study and case–control status.
Unconditional logistic models were used to estimate
odds ratios (ORs) and 95% confidence intervals (CIs).
Minimally adjusted models controlled for age, study,
ethnicity and education level (categorical, see
Table 1). Multivariate-adjusted models were further
adjusted for pack-years of cigarette smoking (contin-
uous) and drinks per day (continuous). Because
cigarette smoking status was associated with BMI in
our populations (Supplementary Table 1 available as
Supplementary data at IJE online), we were con-
cerned about residual confounding by cigarette smok-
ing. Therefore, we explored separate models with
alternate definitions of cigarette smoking, including
log-transformed cigarette-years, square root of
pack-years with ever smoking status and duration of
cigarette smoking with ever smoking status.37,38 The
P-values for linear trend were calculated using the
ordinal values for the categorical variable in logistic
regression models.
Multivariate-adjusted models among all subjects
were further stratified by cigarette smoking and alco-
hol drinking status (non-drinking and non-smoking,
and non-smoking and non-drinking subjects), age
(<50, 550 years), sex, study centre and geographical
region (Europe, North America, Latin America and
Asia) and whether the study collected population-
based or hospital-based controls. Cigarette smokers
were further stratified by smoking status (never,
current, former), duration of smoking (420,420 to
<40, 540 years), number of cigarettes smoked per
day (<15, 15–20, 21–30, 531) among current smo-
kers, and for former smokers time since quitting
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smoking (410,410 to <20, 520 years). HNC cases
were stratified by tumour histology and site.
Effect measure modification was evaluated by testing
for deviation from a multiplicative interaction model,
using the log-likelihood ratio test to compare the fit of
logistic models with and without an interaction term.
Between-study heterogeneity was also examined
using the likelihood ratio test.
Results
Study population characteristics
A total of 12 716 cases and 17 438 controls had
anthropometry data. Among these participants, cases
were older and more likely to be male, shorter in
stature (<1.65 m), cigarette smoker and alcohol drin-
ker compared with controls (Table 1). Furthermore,
cases were heavier cigarette smokers and alcohol drin-
kers than controls. Most (71.4%) cases were squa-
mous cell carcinomas. Approximately 70% of cases
were diagnosed with cancers of the oro- and
hypo-pharynx or larynx, and 30% of the cases were
diagnosed with cancers of the oral cavity. A majority
of the studies selected controls from hospital patients.
BMI
Lean subjects at reference (BMI4 18.5 kg/m2)
had twice the risk of HNC (multivariate-adjusted
OR¼ 2.13, 95% CI 1.75–2.58; Table 2), compared
Table 2 Adjusteda ORs and 95% CIs for the association between HNC and BMI
BMI measures
Cases Controls Minimally-adjusted
b Multivariate-adjustedc
n (%) n (%) OR (95% CI) OR (95% CI)
BMI (kg/m2) at referenced,e
<18.5 918 (8.7) 382 (2.5) 2.57 (2.20–2.99) 2.13 (1.75–2.58)
18.5–24.9 5749 (54.6) 6255 (41.5) 1.00 1.00
25.0–29.9 2855 (27.1) 6069 (40.3) 0.47 (0.41–0.53) 0.52 (0.44–0.60)
530.0 1011 (9.6) 2359 (15.7) 0.43 (0.35–0.53) 0.43 (0.33–0.57)
P-value for study heterogeneity <0.01 <0.01
P for trendf <106 <106
BMI (kg/m2) at 2–5 years before referenceg
<18.5 481 (8.4) 203 (3.6) 1.88 (1.06–3.33) 1.56 (0.80–3.02)
18.5–24.9 3159 (55.4) 2456 (43.0) 1.00 1.00
25.0–29.9 1523 (26.7) 2072 (36.3) 0.55 (0.44–0.68) 0.57 (0.48–0.68)
530.0 538 (9.4) 980 (17.2) 0.43 (0.31–0.61) 0.46 (0.30–0.72)
P-value for study heterogeneity <0.01 <0.01
P-value for trendf 0.000295 0.0011
BMI (kg/m2) between 20 and 30 years of ageh
<18.5 415 (6.3) 579 (6.7) 0.99 (0.80–1.22) 0.91 (0.72–1.15)
18.5–24.9 4708 (71.9) 5911 (68.6) 1.00 1.00
25.0–29.9 1232 (18.8) 1748 (20.3) 0.88 (0.74–1.05) 0.88 (0.73–1.04)
530.0 191 (2.9) 375 (4.4) 0.66 (0.48–0.91) 0.62 (0.44–0.86)
P-value for study heterogeneity <0.01 0.03
P-value for trendf 0.13 0.11
aINHANCE pooled case–control study of HNC.
bAdjusted for age, sex, study centres, race and education level.
cAdjusted for age, sex, race, education level, study centres, pack-year of cigarette smoking, lifetime duration of pipe use, lifetime
duration of cigar use and alcohol drinks per day.
dDate of reference is defined as the date of diagnosis for cases and date of selection for controls.
eAggregate estimates are based on data from the following studies: France, Milan, Tampa, Puerto Rico, Switzerland, North
Carolina, Aviano, Italy multicentre, Houston, Boston, New York, Los Angeles and South America.
fP-values for linear trend was calculated using the ordinal values for the categorical variable.
gAggregate estimates are based on data from the following studies: Central Europe, New York, Seattle, Boston, South America and
IARC Multicentre.
hAggregate estimates are based on data from the following studies: Italy Multicentre, Centrale Europe, Los Angeles, Puerto Rico,
South America and IARC Multicentre.
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with subjects with a BMI between 418.5 and
25.0 kg/m2. Conversely, HNC risk was inversely asso-
ciated with being overweight (BMI425.0–30.0 kg/m2)
or obese (BMI430.0 kg/m2) at reference (multi-
variate-adjusted OR¼ 0.52, 95% CI 0.44–0.60;
multivariate-adjusted OR¼ 0.43, 95% CI 0.33–0.57,
respectively; Table 2), adjusting for pack-years of cig-
arette smoking, duration of cigar and pipe smoking
and duration of alcohol consumption (Figure 1).
Comparing the minimally adjusted and the
multivariate-adjusted ORs, it is evident that pack-
years of cigarette smoking, lifetime duration of pipe
use, lifetime duration of cigar use and alcohol drinks
per day did not meaningfully confound the associa-
tion between BMI and HNC risk. However, we further
evaluated the influence of possible residual confound-
ing from cigarette smoking among all subjects by
controlling for alternative definitions of cigarette
smoking (including log-transformed cigarette-years,
square root of pack-years with ever smoking status
and duration of cigarette smoking with ever smoking
status);37,38 however, these alternate definitions of
cigarette smoking did not alter the results for BMI
(data not shown).
Results for BMI 2–5 years prior to the reference
date were similar to the results for BMI at
reference (Table 2). Furthermore, BMI430.0 kg/m2
at age 20–30 years was associated with a lower
risk of HNC (multivariate-adjusted OR¼ 0.62, 95%
CI 0.44–0.86) compared with subjects with BMI
418.5–25.0 kg/m2. No association was found between
leanness (BMI < 18.5 kg/m2) at age 20–30 years and
risk of HNC (multivariate-adjusted OR¼ 0.91, 95% CI
0.72–1.15). Additional analyses restricted to studies
that reported all three BMI time points (including
BMI at reference, 2–5 years prior to reference and at
age 20–30 years) were not undertaken due to the
small numbers from two studies (Latin American
and IARC multicentre studies).
The direction of the risk estimates found in Table 2
was similar to those for individual studies, although
the magnitude of the association differed significantly
across studies (P-value for between-study heterogene-
ity was <0.01), and there were no patterns by geo-
graphical region (Supplementary Table 2 available as
Supplementary data at IJE online). The ORs and 95%
CIs from random effects models (data not shown)
were similar to those shown in Table 2 from fixed
effect models.
Effect measure modification by cigarette
smoking and alcohol consumption
Among never tobacco smokers and never alcohol
drinkers (Table 3), the associations for overweight
(multivariate-adjusted OR¼ 0.94, 95% CI 0.49–1.80)
and obese (multivariate-adjusted OR¼ 0.95, 95% CI
0.47–1.91) subjects were attenuated towards the
null, whereas lean subjects at reference experienced
an elevated risk of HNC (multivariate-adjusted
OR¼ 3.13, 95% CI 0.73–13.40). The elevated risk asso-
ciated with leanness was sustained for BMI 2–5 years
prior to reference and for BMI at age 20–30 years
among never tobacco smokers and never alcohol
drinkers. Overweight and obesity were not associated
with a lower risk of HNC at BMI 2–5 years before
reference or at age 20–30 years (Table 3). Supplemen-
tary Tables S3 and S4 (available as Supplementary
data at IJE online) show BMI associations stratified
by tobacco use only and adjusted for alcohol intake,
and stratified by alcohol use only adjusted for tobacco
use, respectively. Overall, leanness at reference was
inversely associated with HNC risk in all strata.
BMI425 kg/m2 was associated with HNC risk in all
strata with the exception of never tobacco users
(425.0–30.0 kg/m2: multivariate-adjusted OR¼ 0.84,
95% CI 0.70–1.00; 430 kg/m2: multivariate-adjusted
Figure 1 Forest plot of study-specific ORs and 95% CIs for
the association between HNC risk and BMI reported at
reference with categories of <18.5 kg/m2 (leanness, A),
25.0 to <30.0 kg/m2 (overweight, B) and 30.0–60.0 kg/m2
(obese, C), compared with 18.5 to <25.0 kg/m2 (normal).
Studies are weighted according to the inverse of the
variation of the log OR. The size of the boxes indicates
the variance of the log OR.
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OR¼ 0.82, 95% CI 0.65–1.02; Supplementary Table 5
available as Supplementary data at IJE online).
Among tobacco users, we further examined the rela-
tionship between BMI and risk of HNC by character-
istics of smoking habits (Supplementary Tables 5–7
available as Supplementary data at IJE online).
Similar to results presented overall (Table 2), obesity
(at reference, 2–5 years prior to reference and at age
20–30 years) was associated with lower risk of HNC
among both current and former tobacco users
(Supplementary Table 5 available as Supplementary
data at IJE online). Leanness was associated with
higher risk of HNC among current smokers
(multivariate-adjusted OR¼ 2.11, 95% CI 1.48–3.01;
Supplementary Table 5 available as Supplementary
data at IJE online), persisted for current smoking of
<15, 15–20 and 21–30 cigarettes/day, but was weaker,
albeit imprecise, for smokers of 430 cigarettes/day
(multivariate-adjusted OR¼ 1.27, 95% CI 0.79–2.03;
Supplementary Table 6 available as Supplementary
data at IJE online). Current smokers had a 51 and
62% lower risk, respectively, associated with being
overweight or obese, compared with current smokers
with BMI 418.5–25.0 kg/m2 (multivariate-adjusted
OR¼ 0.49, 95% CI 0.43–0.56 and OR¼ 0.38, 95% CI
0.27–0.54, respectively, Supplementary Table 5 avail-
able as Supplementary data at IJE online), regardless
of number of cigarettes per day (Supplementary
Table 6 available as Supplementary data at IJE
online). The multivariate-adjusted ORs for BMI at
Table 3 Multivariate-adjusted ORs and 95% CIs for the association between HNC and BMI by alcohol drinking and
cigarette smoking statusa
BMI measures
Among never tobacco smokers
and never alcohol drinkers
Among ever tobacco smokers
and ever alcohol drinkers
Case
n (%)
Control
n (%) ORb (95% CI)
Case
n (%)
Control
n (%) ORc (95% CI)
BMI (kg/m2) at referenced,e
<18.5 40 (8.3) 118 (4.8) 3.13 (0.73–13.40) 650 (7.7) 167 (2.1) 2.01 (1.60–2.52)
18.5–24.9 183 (38.0) 1017 (41.4) 1.00 4794 (55.0) 3287 (42.0) 1.00
25.0–29.9 145 (30.0) 859 (35.0) 0.94 (0.49–1.80) 2271 (26.1) 3222 (41.2) 0.50 (0.45–0.56)
530.0 113 (23.5) 461 (18.8) 0.95 (0.47–1.91) 695 (8.0) 1142 (14.6) 0.38 (0.30–0.49)
P-value for study heterogeneity 0.02 0.01
P for trendf 0.49 <106
BMI (kg/m2) 2–5 years before referenceg
<18.5 28 (12.0) 81 (8.8) 2.64 (1.50–4.67) 245 (5.4) 73 (2.3) 1.39 (0.80–2.44)
18.5–24.9 93 (39.9) 419 (45.5) 1.00 2598 (57.7) 1335 (42.5) 1.00
25.0–29.9 70 (30.0) 271 (29.5) 0.97 (0.67–1.41) 1259 (28.0) 1196 (38.1) 0.58 (0.49–0.68)
530.0 42 (18.0) 149 (16.2) 1.09 (0.70–1.71) 398 (8.8) 539 (17.1) 0.42 (0.29–0.60)
P-value for study heterogeneity 0.02 0.03
P-value for trendf 0.17 0.00042
BMI (kg/m2) between 20 and 30 years of ageh
<18.5 24 (10.8) 99 (8.9) 1.76 (0.98–3.19) 326 (5.9) 271 (5.7) 0.88 (0.73–1.07)
18.5–24.9 135 (60.5) 743 (66.6) 1.00 4038 (73.2) 3333 (69.6) 1.00
25.0–29.9 50 (22.4) 218 (19.5) 1.26 (0.84–1.90) 1018 (18.4) 1001 (20.9) 0.82 (0.73–0.91)
530.0 14 (6.3) 56 (5.0) 1.15 (0.57–2.35) 137 (2.5) 185 (3.9) 0.50 (0.39–0.65)
P-value for study heterogeneity 0.08 0.36
P for trendf 0.90 <105
aINHANCE pooled case–control study of HNC.
bAdjusted for age, sex, study centres, race and education level.
cAdjusted for age, sex, race, education level, study centres, pack-year of cigarette smoking, lifetime duration of pipe use, lifetime
duration of cigar use and alcohol drinks per day.
dDate of reference is defined as the date of diagnosis for cases and date of selection for controls.
eAggregate estimates are based on data from the following studies: France, Milan, Tampa, Puerto Rico, Switzerland, Aviano, Italy
multicentre, Houston, Boston, New York, Los Angeles and South America.
fP-values for linear trend was calculated using the ordinal values for the categorical variable.
gAggregate estimates are based on data from the following studies: Central Europe, New York, Seattle, Boston, South America and
IARC Multicentre.
hAggregate estimates are based on data from the following studies: Italy Multicentre, Central Europe, Los Angeles, Puerto Rico,
South America and IARC Multicentre.
BODY SIZE AND HEAD AND NECK CANCER 1097
reference and 2–5 years from reference were slightly
closer to the null for former tobacco users than those
observed for current tobacco users (P-value for inter-
action was 40.0001; Supplementary Table 5 available
as Supplementary data at IJE online). As the number
of years since quitting increased, the decreased risk
associated with obesity and the increased risk asso-
ciated with leanness diminished (Supplementary
Table 7 available as Supplementary data at IJE
online). Results were similar whether any tobacco
product (data not shown) or cigarette tobacco (as
shown in tables presented here) were considered.
The inverse association for obesity appeared to be
slightly stronger for heavier drinkers than for lighter
drinkers or non-drinkers (Supplementary Table 8
available as Supplementary data at IJE online).
Effect measure modification by other factors
Although the estimates for leanness, compared with
BMI 18.5–25.0 kg/m2, were consistently elevated for
risk of site-specific HNC, the ORs were stronger, ran-
ging from 2.20 to 2.85, for squamous cell carcinomas
risk of the oral cavity, hypopharynx and oropharynx
compared with the 1.6 fold higher risk of laryngeal/
oral cancer (Supplementary Table 9 available as
Supplementary data at IJE online). The inverse asso-
ciations with larger body size also varied by
site-specific HNC risk but all estimates exhibited a
decreased association (Supplementary Table 9 avail-
able as Supplementary data at IJE online). The asso-
ciation between body size and HNC risk was in
similar directions for both men and women (Supple-
mentary Table 10 available as Supplementary data at
IJE online), although the magnitude of the associa-
tion for BMI at reference was significantly different
than that for men (P-value for interaction was 0.004).
Age was also an effect measure modifier for leanness
at reference and 2–5 years prior to reference, although
estimates for overweight and obesity were similar for
subjects <50 and 550 years (Supplementary Table 11
available as Supplementary data at IJE online). Sup-
plementary Table 12 (available as Supplementary data
at IJE online) displays the ORs for BMI by the type of
control selection used in the study designs. ORs were
similar despite the source of controls for BMI at
reference and BMI at age 20–30 years, although the
association for BMI 2–5 years prior to reference
was stronger for studies with hospital-based controls
compared with those with population-based controls.
Discussion
In a pooled analysis of 17 international studies, we
found that lean subjects were at higher risk of HNC,
whereas heavy subjects were at a lower risk, com-
pared with subjects with a normal body size, after
adjustment for major HNC risk factors, cigarette
smoking and alcohol drinking. These results confirm
the inverse association between BMI and HNC risk
observed in previous studies.5–13 Although these
individual studies had fewer subjects who were
non-smokers and non-drinkers to obtain estimates
that were independent of smoking and alcohol use.
We found that the elevated risk of HNC observed
among lean subjects was evident among cigarette
smokers and alcohol drinkers, as well as non-smokers
and non-drinkers. However, the reduced risk related
to higher BMI was limited only to cigarette smokers
and alcohol drinkers in our analysis. Furthermore,
examination of stratification by only tobacco use or
only alcohol use suggested that the association
between BMI and HNC risk was more confounded
by tobacco use.
One explanation for our findings is that, in the time
shortly before diagnosis, undiagnosed cancer lesions
in the head and neck may cause dysphagia or odyno-
phagia or may alter taste and appetite, leading to a
reduction of overall caloric intake and weight loss.
For example, in a study of 407 patients with newly
diagnosed second primary or recurrent tumours, on
average, a 5–10% weight loss before diagnosis in
30–53% of cases was observed.39 Reported weight,
therefore, may misrepresent usual adult weight,
which may be the more biologically relevant time
frame. A 5–10% weight loss prior to diagnosis of
cases may shift some cases into a lower BMI category
at the time of study interview. If it is assumed that
25–50% of the reportedly lean subjects in our study
had a ‘true’ normal adult body size then the corrected
unadjusted OR for leanness would be 2.01 (95% CI
1.76–2.29) to 1.21 (95% CI 1.05–1.40). These esti-
mates suggest that misclassification bias would need
to be quite prevalent before risk estimates for lean-
ness are significantly attenuated towards the null and
thus modify our conclusions. Lastly, assuming 25% of
our reportedly lean cases had a normal adult BMI and
25% of our reportedly normal weight cases had a true
overweight BMI during adulthood, the OR for lean-
ness would move farther from the null (OR¼ 2.65,
95% CI 2.32–3.02), whereas the OR for overweight
would move towards the null (OR¼ 0.97, 95% CI
0.92–1.03), indicating the robustness of leanness esti-
mates to the influence of differential misclassification,
but casting some doubt on our estimates for over-
weight subjects. Furthermore, we found that leanness
self reported 2–5 years prior to reference was also
associated with elevated risk of HNC. In aggregate,
these observations suggest that recent weight loss in
cases is unlikely to cause a substantial bias to our
observed results for leanness at reference (at diagno-
sis for cases).
Obesity, but not leanness, between 20 and 30 years
of age was associated with lower risk for HNC.
However, among people who never smoked or
drank, data suggested an increase in risk with lean-
ness and little to no association with being over-
weight or obese. Taken together with results for
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BMI over the life course, a predisposition for leanness
at a young age may increase risk of HNC in subjects
who do not drink or smoke. In contrast, drinkers and
smokers who were also overweight or obese at any
age appear to have a lower risk of HNC.
Elevated risks among lean subjects and reduced
risks among overweight and obese subjects have
also been found for other smoking-related malignan-
cies, including cancers of the lung 40–45 and squamous
cell carcinoma of the esophagus.46 These consistent
findings from prospective cohort and retrospective
case–control studies suggest that weight loss due to
pre-existing conditions is unlikely to account for
the observed associations. Moreover, exclusions of
people who died in the first 5 years of follow-up
and those with pre-existing disease in one prospective
study did not significantly alter results,42 which
further suggests weight loss measured close to disease
onset, such as in case–control studies represented
here, does not appreciably contribute to exposure
misclassification. These results, however, do not pro-
vide additional insight to whether cigarette smoking
confounds or modifies the relationship between body
size and risk of these smoking-related cancers.
In the prospective studies of lung cancer,41,42,44 the
associations between leanness and mortality or inci-
dence was minimally affected when adjusted for
smoking, and weaker, although still evident, in
non-smokers.41,42,44
Another possible explanation for our BMI findings
stratified by alcohol/smoking status is that the under-
lying etiology and molecular mechanisms of smoking-
related malignancies do not apply to those that
develop in non-smokers.47 For example, in lung
cancer,47 it has been shown that the somatic alter-
ations in key tumour suppressor and oncogenes, risk
factors and clinical features differ among smokers
and non-smokers. If this is also true for tumours
of the head and neck, it is possible that differences
we observed in effect estimates between smokers
and non-smokers may indicate true modification
of risk.
Inconsistent definitions of a cigarette smoker and an
alcohol drinker across studies may have led to the
inclusion of some individuals who minimally used
tobacco or alcohol into the ‘never user of tobacco’
and ‘never drinker’ categories as defined in this
study3,44 and in a study of lung cancer,44 which
may be a potential source of study heterogeneity
detected in our effect estimates. However, estimated
ORs for individual studies were in similar directions
and differed only in the magnitude of the associa-
tion. The exact sources of differences between studies
are unknown, but our stratified analyses suggest that
they are unlikely to be due to geographical region or
sources of controls. The accuracy of self-reported
height and weight is high for men and women but
slightly lower for obese individuals.48 Yet, even small
underestimations of weight, accompanied by
overestimations of height, can shift an individual’s
BMI into a lower category. A downward shift in
BMI, calculated from self-reported height and
weight in our study, is likely to be non-differential
with respect to case–control status. Our results for
BMI at age 20–30 years self-reported at reference
may be particularly prone to random misclassification
and may explain why these estimates are closer to the
null. We were further limited to evaluating the
association with body size since we only had infor-
mation on BMI, which is a measure of overall
adiposity.49
There has been limited research on connections
between leanness and likely mechanisms of head
and neck carcinogenesis, although altered caloric
absorption and utilization as well as levels of oxida-
tive stress markers and DNA adducts have been
proposed to mediate the relationship between body
size and HNC risk.14–16,50–55 Some,50,51 but not all,
studies have shown that lean, compared with heavy
but otherwise healthy, adults have higher urinary
levels of 8-hydroxydeoxyguanosine (8-OHdG), a
marker of oxidative DNA damage that is also elevated
in smokers.52–54 This relationship was stronger51 or
only evident53 among cigarette smokers but not
non-smokers. Similarly, DNA adducts, which
represent an integrated indicator of exposure, metab-
olism and DNA repair, have also been observed to be
higher in lean, compared with overweight, smokers.55
If greater propensity for elevated levels of oxidative
stress markers and DNA adducts explains the associ-
ation between leanness and higher HNC risk among
smokers, we would not expect to have observed a
higher risk of HNC for lean people regardless of
smoking status, and an inverse association with over-
weight and obese people only among smokers and
drinkers. Moderate smokers, who on average weigh
less than non-smokers,14–16 despite similar caloric
intakes, have been hypothesized to have higher
smoking-induced metabolism and caloric utilization
or loss due to faster bowel motility.14 However, the
distribution of BMI in our control populations was
unrelated to number of cigarettes smoked per day,
and the lower risk for higher BMI and elevated risk
for leanness persisted across categories of number of
cigarettes smoked per day. Additional studies are
needed to explore biological pathways that mediate
the relationship between body size and head and
neck and other smoking-related cancers.
Based on a large pool of case–control studies, our
findings provide the strongest evidence to date that
leanness is a risk factor for HNC independent of the
confounding effects of cigarette smoking and alcohol
drinking. Stronger tests of the relationship between
BMI and HNC could come from large prospective
cohorts to eliminate the possibility of bias due to
pre-existing conditions, as well as functional studies,
to explain the relationship between body size and
HNC risk. Although only a small portion of adults
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are lean,56 our findings, if confirmed, may shed light
on biological mechanisms independent of tobacco
smoke and ethanol consumption.
Supplementary Data
Supplementary data are available at IJE online.
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KEY MESSAGES
 Leanness near the time of diagnosis was associated with higher risk of HNC among all participants,
including those who did not drink alcohol or smoke cigarettes.
 Excess adiposity may be associated with lower risk of HNC, although the relationship may be limited
to drinkers and smokers.
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